{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:43:06Z","timestamp":1792622586208,"version":"4.5.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>ApTOLL is a TLR4 antagonist with proven preclinical neuroprotective effect and a safe profile in healthy volunteers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the safety and efficacy of ApTOLL in combination with endovascular treatment (EVT) for patients with ischemic stroke.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This phase 1b\/2a, double-blind, randomized, placebo-controlled study was conducted at 15 sites in Spain and France from 2020 to 2022. Participants included patients aged 18 to 90 years who had ischemic stroke due to large vessel occlusion and were seen within 6 hours after stroke onset; other criteria were an Alberta Stroke Program Early CT Score of 6 to 10, estimated infarct core volume on baseline computed tomography perfusion of 5 to 70 mL, and the intention to undergo EVT. During the study period, 4174 patients underwent EVT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>In phase 1b, 0.025, 0.05, 0.1, or 0.2 mg\/kg of ApTOLL or placebo; in phase 2a, 0.05 or 0.2 mg\/kg of ApTOLL or placebo; and in both phases, treatment with EVT and intravenous thrombolysis if indicated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary end point was the safety of ApTOLL based on death, symptomatic intracranial hemorrhage (sICH), malignant stroke, and recurrent stroke. Secondary efficacy end points included final infarct volume (via MRI at 72 hours), NIHSS score at 72 hours, and disability at 90 days (modified Rankin Scale [mRS] score).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In phase Ib, 32 patients were allocated evenly to the 4 dose groups. After phase 1b was completed with no safety concerns, 2 doses were selected for phase 2a; these 119 patients were randomized to receive ApTOLL, 0.05 mg\/kg (n\u2009=\u200936); ApTOLL, 0.2 mg\/kg (n\u2009=\u200936), or placebo (n\u2009=\u200947) in a 1:1:\u221a2 ratio. The pooled population of 139 patients had a mean (SD) age of 70 (12) years, 81 patients (58%) were male, and 58 (42%) were female. The primary end point occurred in 16 of 55 patients (29%) receiving placebo (10 deaths [18.2%], 4 sICH [7.3%], 4 malignant strokes [7.3%], and 2 recurrent strokes [3.6%]); in 15 of 42 patients (36%) receiving ApTOLL, 0.05 mg\/kg (11 deaths [26.2%], 3 sICH [7.2%], 2 malignant strokes [4.8%], and 2 recurrent strokes [4.8%]); and in 6 of 42 patients (14%) receiving ApTOLL, 0.2 mg\/kg (2 deaths [4.8%], 2 sICH [4.8%], and 3 recurrent strokes [7.1%]). ApTOLL, 0.2 mg\/kg, was associated with lower NIHSS score at 72 hours (mean difference log-transformed vs placebo, \u221245%; 95% CI, \u221267% to \u221210%), smaller final infarct volume (mean difference log-transformed vs placebo, \u221242%; 95% CI, \u221266% to 1%), and lower degrees of disability at 90 days (common odds ratio for a better outcome vs placebo, 2.44; 95% CI, 1.76 to 5.00).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In acute ischemic stroke, 0.2 mg\/kg of ApTOLL administered within 6 hours of onset in combination with EVT was safe and associated with a potential meaningful clinical effect, reducing mortality and disability at 90 days compared with placebo. These preliminary findings await confirmation from larger pivotal trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04734548\">NCT04734548<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaneurol.2023.1660","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T11:15:19Z","timestamp":1687259719000},"page":"779","source":"Crossref","is-referenced-by-count":96,"title":["Safety and Efficacy of ApTOLL in Patients With Ischemic Stroke Undergoing Endovascular Treatment"],"prefix":"10.1001","volume":"80","author":[{"given":"Macarena","family":"Hern\u00e1ndez-Jim\u00e9nez","sequence":"first","affiliation":[{"name":"aptaTargets, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Hospital Universitario de La Princesa, Universidad Aut\u00f3noma de Madrid, Instituto de Investigaci\u00f3n Sanitaria La Princesa, Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Cotgreave","sequence":"additional","affiliation":[{"name":"Department of Chemical and Pharmaceutical Safety, Division of Bioeconomy and Health, Research Institutes of Sweden, S\u00f6dert\u00e4lje, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Gallego","sequence":"additional","affiliation":[{"name":"Neurological Center of Navarra, Navarra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Jilma","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Flores","sequence":"additional","affiliation":[{"name":"Stroke Unit, Hospital Joan XXIII, Tarragona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tudor G.","family":"Jovin","sequence":"additional","affiliation":[{"name":"Cooper Neurological Institute, Cherry Hill, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Vivancos","sequence":"additional","affiliation":[{"name":"Stroke Unit, Department of Neurology, Hospital La Princesa, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Hern\u00e1ndez-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Stroke Unit, Department of Neuroscience Hospital Germans Trias I Pujol, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Molina","sequence":"additional","affiliation":[{"name":"Stroke Unit, Department of Neurology, Hospital Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Montaner","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Macarena, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Casariego","sequence":"additional","affiliation":[{"name":"Aldebaran Health Intelligence, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Dalsgaard","sequence":"additional","affiliation":[{"name":"Cureteq, Zug, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Liebeskind","sequence":"additional","affiliation":[{"name":"Neurovascular Imaging Research Core, Department of Neurology, UCLA Stroke Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Cobo","sequence":"additional","affiliation":[{"name":"Statistics and Operations Research, Barcelona-Tech, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Castellanos","sequence":"additional","affiliation":[{"name":"Department of Neurology, Complejo Hospitalario Universitario\/Biomedical Research Institute, A Coru\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere Cardona","family":"Portela","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Universitari Bellvitge, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Masju\u00e1n","sequence":"additional","affiliation":[{"name":"Stroke Unit, Department of Neurology, Ram\u00f3n y Cajal University Hospital, Departamento de Medicina, Facultad de Medicina, Universidad de Alcal\u00e1, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Moniche","sequence":"additional","affiliation":[{"name":"Stroke Unit, Department of Neurology, Virgen del Rocio University Hospital, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ignacio","family":"Tembl","sequence":"additional","affiliation":[{"name":"Stroke Unit, Department of Neurology, La Fe Hospital, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikel","family":"Terce\u00f1o Izaga","sequence":"additional","affiliation":[{"name":"Stroke Unit, Department of Neurology, Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Girona, Hospital Doctor Josep Trueta de Girona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Arenillas","sequence":"additional","affiliation":[{"name":"Stroke Unit, Department of Neurology, Hospital de Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Calleja","sequence":"additional","affiliation":[{"name":"Department of Neurology and Stroke Center, University Hospital 12 de Octubre, Instituto de Investigaci\u00f3n Hospital 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Marc","family":"Olivot","sequence":"additional","affiliation":[{"name":"Department of Vascular Neurology and Clinical Investigating Center 1435, Toulouse University Hospital, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Calviere","sequence":"additional","affiliation":[{"name":"Department of Vascular Neurology and Clinical Investigating Center 1435, Toulouse University Hospital, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Henon","sequence":"additional","affiliation":[{"name":"University Lille, Inserm, CHU Lille, U1172, Lille Neuroscience and Cognition, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Mazighi","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM 1148, Department of Neurology, Hopital Lariboisi\u00e8re-APHP Nord, and Interventional Neuroradiology, Hopital Fondation Adolphe Rothschild, FHU Neurovasc, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pi\u00f1eiro","sequence":"additional","affiliation":[{"name":"aptaTargets, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pugliese","sequence":"additional","affiliation":[{"name":"aptaTargets, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Aptus Biotech, Madrid, Spain"},{"name":"Grupo de Apt\u00e1meros, Departamento de Bioqu\u00edmica-Investigaci\u00f3n, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria, Ram\u00f3n y Cajal University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Angeles","family":"Moro","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n Neurovascular, Department of Pharmacology and Toxicology, Faculty of Medicine, Universidad Complutense, Instituto de Investigaci\u00f3n Hospital 12 de Octubre, Madrid, Spain"},{"name":"Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Garcia-Tornel","sequence":"additional","affiliation":[{"name":"Stroke Unit, Department of Neurology, Hospital Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Lizasoain","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n Neurovascular, Department of Pharmacology and Toxicology, Faculty of Medicine, Universidad Complutense, Instituto de Investigaci\u00f3n Hospital 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ribo","sequence":"additional","affiliation":[{"name":"aptaTargets, Madrid, Spain"},{"name":"Stroke Unit, Department of Neurology, Hospital Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"24","key":"noi230037r1","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke.","volume":"333","author":"National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group","year":"1995","journal-title":"N Engl J Med"},{"issue":"10029","key":"noi230037r2","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/S0140-6736(16)00163-X","article-title":"Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials.","volume":"387","author":"Goyal","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"noi230037r3","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1056\/NEJMc1801530","article-title":"Thrombectomy 6 to 24 hours after stroke.","volume":"378","author":"Jovin","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"noi230037r4","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1056\/NEJMoa1713973","article-title":"Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging.","volume":"378","author":"Albers","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"noi230037r5","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1056\/NEJMoa2118191","article-title":"Endovascular therapy for acute stroke with a large ischemic region.","volume":"386","author":"Yoshimura","year":"2022","journal-title":"N Engl J Med"},{"issue":"10227","key":"noi230037r6","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(20)30258-0","article-title":"Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial.","volume":"395","author":"Hill","year":"2020","journal-title":"Lancet"},{"issue":"24","key":"noi230037r7","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1056\/NEJMoa1503780","article-title":"Thrombectomy within 8 hours after symptom onset in ischemic stroke.","volume":"372","author":"Jovin","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"noi230037r8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411587","article-title":"A randomized trial of intraarterial treatment for acute ischemic stroke.","volume":"372","author":"Berkhemer","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"noi230037r9","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1161\/CIRCULATIONAHA.106.603431","article-title":"Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke.","volume":"115","author":"Caso","year":"2007","journal-title":"Circulation"},{"issue":"4","key":"noi230037r10","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1161\/STROKEAHA.107.498212","article-title":"Toll-like receptor 4 is involved in subacute stress-induced neuroinflammation and in the worsening of experimental stroke.","volume":"39","author":"Caso","year":"2008","journal-title":"Stroke"},{"issue":"6","key":"noi230037r11","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1161\/STROKEAHA.116.015956","article-title":"Toll-like receptor 4 mediates hemorrhagic transformation after delayed tissue plasminogen activator administration in in situ thromboembolic stroke.","volume":"48","author":"Garc\u00eda-Culebras","year":"2017","journal-title":"Stroke"},{"issue":"6","key":"noi230037r12","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/jcbfm.2010.231","article-title":"Toll-like receptors 2 and 4 in ischemic stroke: outcome and therapeutic values.","volume":"31","author":"Brea","year":"2011","journal-title":"J Cereb Blood Flow Metab"},{"issue":"4","key":"noi230037r13","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1161\/STROKEAHA.118.023927","article-title":"Stroke treatment academic industry roundtable X: brain cytoprotection therapies in the reperfusion era.","volume":"50","author":"Savitz","year":"2019","journal-title":"Stroke"},{"issue":"6","key":"noi230037r14","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1161\/01.CIR.0000112575.66565.84","article-title":"Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice.","volume":"109","author":"Oyama","year":"2004","journal-title":"Circulation"},{"issue":"8","key":"noi230037r15","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/j.ymthe.2018.05.019","article-title":"TLR4-binding DNA aptamers show a protective effect against acute stroke in animal models.","volume":"26","author":"Fern\u00e1ndez","year":"2018","journal-title":"Mol Ther"},{"issue":"8","key":"noi230037r16","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3390\/biom10081167","article-title":"Targeting TLR4 with ApTOLL improves heart function in response to coronary ischemia reperfusion in pigs undergoing acute myocardial infarction.","volume":"10","author":"Ramirez-Carracedo","year":"2020","journal-title":"Biomolecules"},{"key":"noi230037r17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.omtn.2022.03.005","article-title":"First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: safety and pharmacokinetics in healthy volunteers.","volume":"28","author":"Hern\u00e1ndez-Jim\u00e9nez","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"noi230037r18","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1127585","article-title":"APRIL: a double-blind, placebo-controlled, randomized, phase Ib\/IIa clinical study of ApTOLL for the treatment of acute ischemic stroke.","volume":"14","author":"Hern\u00e1ndez-Jim\u00e9nez","year":"2023","journal-title":"Front Neurol"},{"issue":"11","key":"noi230037r19","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1161\/01.STR.25.11.2220","article-title":"Improved reliability of the NIH Stroke Scale using video training.","volume":"25","author":"Lyden","year":"1994","journal-title":"Stroke"},{"issue":"5","key":"noi230037r20","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/01.STR.19.5.604","article-title":"Interobserver agreement for the assessment of handicap in stroke patients.","volume":"19","author":"van Swieten","year":"1988","journal-title":"Stroke"},{"issue":"8","key":"noi230037r21","first-page":"1534","article-title":"Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke.","volume":"22","author":"Pexman","year":"2001","journal-title":"AJNR Am J Neuroradiol"},{"issue":"2","key":"noi230037r22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1161\/STROKEAHA.120.032025","article-title":"Defining a target population to effectively test a neuroprotective drug.","volume":"52","author":"Oliv\u00e9-Gadea","year":"2021","journal-title":"Stroke"},{"issue":"6","key":"noi230037r23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/neurintsurg-2018-014568","article-title":"European Stroke Organisation (ESO)- European Society for Minimally Invasive Neurological Therapy (ESMINT) guidelines on mechanical thrombectomy in acute ischemic stroke.","volume":"11","author":"Turc","year":"2019","journal-title":"J Neurointerv Surg"},{"issue":"3","key":"noi230037r24","doi-asserted-by":"publisher","first-page":"I","DOI":"10.1177\/23969873221100032","article-title":"European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack.","volume":"7","author":"Dawson","year":"2022","journal-title":"Eur Stroke J"},{"issue":"5","key":"noi230037r25","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/neurintsurg-2018-014127","article-title":"eTICI reperfusion: defining success in endovascular stroke therapy.","volume":"11","author":"Liebeskind","year":"2019","journal-title":"J Neurointerv Surg"},{"issue":"4","key":"noi230037r26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.nrleng.2019.03.019","article-title":"Validation of the Spanish-language version of the simplified modified Rankin Scale telephone questionnaire.","volume":"37","author":"Fern\u00e1ndez Sanz","year":"2022","journal-title":"Neurologia (Engl Ed)"},{"issue":"9558","key":"noi230037r27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0140-6736(07)60149-4","article-title":"Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.","volume":"369","author":"Wahlgren","year":"2007","journal-title":"Lancet"},{"issue":"9","key":"noi230037r28","doi-asserted-by":"publisher","first-page":"11753","DOI":"10.3390\/ijms130911753","article-title":"Neuroprotection for stroke: current status and future perspectives.","volume":"13","author":"Minnerup","year":"2012","journal-title":"Int J Mol Sci"},{"issue":"6","key":"noi230037r29","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1161\/STROKEAHA.117.017040","article-title":"Combining neuroprotection with endovascular treatment of acute stroke: is there hope?","volume":"48","author":"Tymianski","year":"2017","journal-title":"Stroke"},{"issue":"12","key":"noi230037r30","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1161\/STROKEAHA.117.017283","article-title":"Reconsidering neuroprotection in the reperfusion era.","volume":"48","author":"Savitz","year":"2017","journal-title":"Stroke"},{"issue":"9","key":"noi230037r31","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1161\/STROKEAHA.117.017112","article-title":"Translational stroke research: vision and opportunities.","volume":"48","author":"Bosetti","year":"2017","journal-title":"Stroke"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2806243\/jamaneurology_hernndezjimnez_2023_oi_230037_1708711200.70278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T11:00:25Z","timestamp":1708945225000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2806243"}},"subtitle":["A Phase 1\/2 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2023.1660","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}